Cancer tailored next generation cellular therapies

Project Information

CATACLIS

Grant agreement ID: 101124203

DOI

10.3030/101124203

EC signature date 30 April 2024

Start date 1 October 2024

End date 30 September 2029

Funded under

• European Research Council (ERC)

Total cost

€ 2 000 000,00

EU contribution

€ 2 000 000,00

Coordinated by

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (10)

Serial Killing Assay Using Longitudinal Impedance-Based Tumor Cell Viability Measurement - A Useful Method to Assess T Cell Performance

Author(s): Tengis Tschaidse, Marcel P. Trefny, Emanuele Carlini, David Andreu-Sanz, Stefanos Michaelides, Ngoc Thien Thu Nguyen, Sebastian Kobold
Published in: Journal of Visualized Experiments, 2026, ISSN 1940-087X
Publisher: MyJove Corporation
DOI: 10.3791/69623

Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma

Author(s): Adrian Gottschlich, Ruth Grünmeier, Gordon Victor Hoffmann, Sayantan Nandi, Vladyslav Kavaka, Philipp Jie Müller, Jakob Jobst, Arman Oner, Rainer Kaiser, Jan Gärtig, Ignazio Piseddu, Stephanie Frenz-Wiessner, Savannah D. Fairley, Heiko Schulz, Veronika Igl, Thomas Alexander Janert, Lea Di Fina, Maité Mulkers, Moritz Thomas, Daria Briukhovetska, Donjetë Simnica, Emanuele Carlini, Christina Angeliki Tsiverioti, Marcel P. Trefny, Theo Lorenzini, Florian Märkl, Pedro Mesquita, Ruben Brabenec, Thaddäus Strzalkowski, Sophia Stock, Stefanos Michaelides, Johannes Hellmuth, Martin Thelen, Sarah Reinke, Wolfram Klapper, Pascal Francois Gelebart, Leo Nicolai, Carsten Marr, Eduardo Beltrán, Remco T. A. Megens, Christoph Klein, Fanny Baran-Marszak, Andreas Rosenwald, Michael von Bergwelt-Baildon, Paul J. Bröckelmann, Stefan Endres, Sebastian Kobold
Published in: Blood, Issue 145, 2025, ISSN 0006-4971
Publisher: American Society of Hematology
DOI: 10.1182/BLOOD.2023022197

How CAR T cells can be shielded from prostaglandin E2 signaling to enhance their therapeutic activity

Author(s): Janina Dörr, David Andreu-Sanz, Sebastian Kobold
Published in: Molecular Therapy Oncology, Issue 34, 2026, ISSN 2950-3299
Publisher: Elsevier BV
DOI: 10.1016/J.OMTON.2026.201204

Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors

Author(s): Anne Holtermann, Mila Gislon, Martin Angele, Marion Subklewe, Michael von Bergwelt-Baildon, Kirsten Lauber, Sebastian Kobold
Published in: BioDrugs, Issue 38, 2024, ISSN 1173-8804
Publisher: Springer Science and Business Media LLC
DOI: 10.1007/S40259-024-00669-Y

Tumor microenvironment evolution in lung cancer: Spatio-temporal dynamics and clinical implications

Author(s): Selma Dizdarević, Oleg Timofeev, Daniel Kazdal, Soni Savai Pullamsetti, Rocio Sotillo, Sonja Loges, Sebastian Kobold, Albrecht Stenzinger, Thorsten Stiewe, Rajkumar Savai
Published in: Seminars in Cancer Biology, Issue 123-124, 2026, ISSN 1044-579X
Publisher: Elsevier BV
DOI: 10.1016/J.SEMCANCER.2026.04.003

Ablation of prostaglandin E2 signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours

Author(s): Janina Dörr, Lisa Gregor, Sebastian B. Lacher, Arman Oner, Yi Sun, Ignazio Piseddu, Luisa Fertig, Sebastijan Spajic, Stefanie Lesch, Stefanos Michaelides, Matthias Seifert, Adrian Gottschlich, Natasha Samson, Lina Majed, Daria Briukhovetska, Donjetë Simnica, Viktoria Hartmann, Kathrin Gabriel, Sonia Cohen, Genevieve M. Boland, David Andreu-Sanz, Emanuele Carlini, Sophia Stock, Anne Holtermann, Philipp Jie Müller, Thaddäus Strzalkowski, Marcel P. Trefny, Stefan Endres, Russell W. Jenkins, Jan P. Böttcher, Sebastian Kobold
Published in: Nature Biomedical Engineering, Issue 10, 2026, ISSN 2157-846X
Publisher: Springer Science and Business Media LLC
DOI: 10.1038/S41551-025-01610-6

Long-term consequences of cancer therapy: cognitive impairment following CAR T cell therapy

Author(s): Kathrin Gabriel, Sebastian Kobold
Published in: Signal Transduction and Targeted Therapy, Issue 10, 2025, ISSN 2059-3635
Publisher: Springer Science and Business Media LLC
DOI: 10.1038/S41392-025-02324-6

CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases

Author(s): Adrian-Bogdan Tigu, Madalina Nistor, Diana Gulei, Catalin-Sorin Constantinescu, David Kegyes, Diana Cenariu, Ximena Muresan, Raluca Munteanu, Richard Feder, Ciprian Jitaru, Anamaria Bancos, Maria Santa, Radu Tomai, Marc Damian, Andrei Ivancuta, Ioana Rus, Anca Bojan, Mihnea Zdrenghea, Anca-Dana Buzoianu, Alina Tanase, Hermann Einsele, Sebastian Kobold, Ciprian Tomuleasa
Published in: Blood Reviews, Issue 75, 2026, ISSN 0268-960X
Publisher: Elsevier BV
DOI: 10.1016/J.BLRE.2025.101354

The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity

Author(s): Ngoc Thien Thu Nguyen, Rasmus Müller, Daria Briukhovetska, Justus Weber, Judith Feucht, Annette Künkele, Michael Hudecek, Sebastian Kobold
Published in: Cancers, Issue 16, 2025, ISSN 2072-6694
Publisher: MDPI AG
DOI: 10.3390/CANCERS16142608

Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis

Author(s): David Andreu-Sanz, Lisa Gregor, Emanuele Carlini, Daniele Scarcella, Carsten Marr, Sebastian Kobold
Published in: Journal for ImmunoTherapy of Cancer, Issue 13, 2026, ISSN 2051-1426
Publisher: BMJ
DOI: 10.1136/JITC-2025-011698